Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 9/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | PPIA | P62937 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10377167 | 0.89 | RAB9A (0.70) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL12478850 | 0.86 | HTT (0.53) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL11833609 | 0.83 | HTT (0.68) | MEN1KMT2AHTTMAPK1RAB9A | |
| SCHEMBL12478898 | 0.82 | DHODH (0.65) | MEN1KMT2AHTTMAPK1RAB9A | |
| SCHEMBL4181112 | 0.82 | MEN1 (0.62) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL26631994 | 0.82 | HTT (0.54) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL26742261 | 0.81 | HTT (0.56) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL15635590 | 0.81 | MEN1 (0.58) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL17363143 | 0.81 | MEN1 (0.58) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL12478838 | 0.80 | RAB9A (0.65) | MEN1KMT2AHTTMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2005004818-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004052280-A2 | ANTI-ANGIOGENIC COMPOUNDS AND THEIR USE IN CANCER TREATMENT | IMCLONE SYSTEMS INCORPORATED (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | MEN1 543/4885KMT2A 2240/4885HTT 108/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | MEN1 543/4885KMT2A 2240/4885HTT 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.